Pierrick Martinez

Mr. Pierrick Martinez

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 February 2025 in Cancer Letters
Verified
Journal Article
Closed access
PMPierrick Martinez
Pierrick Martinez
Jean-Marc SabatierJean-Marc Sabatier
Jean-Marc Sabatier

17 April 2024 in Metabolites
Verified
Journal Article
Open access
PDF file
PMPierrick Martinez
Pierrick Martinez
IBIlyes Baghli
Ilyes Baghli
GGGéraud Gourjon
Géraud Gourjon
TSThomas Seyfried
Thomas Seyfried
The cancer paradigm is generally based on the somatic mutation model, asserting that cancer is a disease of genetic origin. The mitochondrial–stem cell connection (MSCC) proposes that tumorigenesis may result from an alteration of the mitochondria, specifically a chronic oxidative phosphorylation (OxPhos) insufficiency in stem cells, which forms cancer stem cells (CSCs) and leads to malignancy. Reviewed evidence suggests that the MSCC could provide a comprehensive understanding of all the different stages of cancer. The metabolism of cancer cells is altered (OxPhos insufficiency) and must be compensated by using the glycolysis and the glutaminolysis pathways, which are essential to their growth. The altered mitochondria regulate the tumor microenvironment, which is also necessary for cancer evolution. Therefore, the MSCC could help improve our understanding of tumorigenesis, metastases, the efficiency of standard treatments, and relapses.

28 June 2026 in Antioxidants
Verified
Journal Article
Open access
PDF file
PMPierrick Martinez
Pierrick Martinez
EMEnrique A Martinez
Enrique A Martinez
LGLionel Gillot
Lionel Gillot
WMWilliam Makis
William Makis
CPCasey Peavler
Casey Peavler
William B. GrantWilliam B. Grant
William B. Grant
Supplements are widely perceived as safe and beneficial; yet in oncology, this assumption is questionable. Clinical trials over the past few decades have often produced disappointing results, raising a critical question: are these agents used correctly, or could they inadvertently cause harm? This review examines supplements frequently used in cancer care—such as oral vitamin C, berberine, N-acetylcysteine, vitamin D, vitamin E, melatonin, polyphenols, alpha-lipoic acid, selenium, and coenzyme Q10—which can act as tumor suppressors or promoters depending on dose, route, and disease stage. We examine their dual antioxidant and pro-oxidant properties, revealing that therapeutic outcomes are shaped not only by the molecule itself, but also by bioavailability, dosing thresholds, and the tumor redox environment. Building on these insights, we propose that four factors may be considered to guide clinical use: ensure that anticancer effects are not overshadowed by antioxidant activity, achieve sufficient bioavailability, confirm pro-oxidant concentrations where possible, and prioritize supplements that target the respiration-supported non-OxPhos pathways. By framing supplements as context-dependent redox modulators rather than universally beneficial agents, this review provides a mechanistically grounded framework for informing future research and safer, more effective integrative oncology strategies.

15 March 2025 in Respiratory Physiology & Neurobiology
Verified
Journal Article
Closed access
PMPierrick Martinez
Pierrick Martinez
MDMathias Dutschmann
Mathias Dutschmann
VEVincent Epercieux
Vincent Epercieux
GGGéraud Gourjon
Géraud Gourjon
FJFabrice Joulia
Fabrice Joulia

3 March 2025 in Journal of Osteopathic Medicine
Verified
Journal Article
Open access
PDF file
FGFlora Gillet
Flora Gillet
MGMathilde Gault
Mathilde Gault
VDVincent Dussault
Vincent Dussault
SCSaïda Cheggour
Saïda Cheggour
MGMarilyne Grinand
Marilyne Grinand
PMPierrick Martinez
Pierrick Martinez
Context: Osteopathic listening tests are diagnostic tools utilized in manual therapies, but their impact on physiological markers of the autonomic nervous system (ANS), such as heart rate (HR) and heart rate variability (HRV), remains unclear. This study examines these effects to clarify the role of listening tests within osteopathic practice. Objectives: This study aims to evaluate the influence of osteopathic listening tests on HR and HRV markers, including the root mean square of successive differences (rMSSD) and the low-frequency/high-frequency (LF/HF) ratio, in healthy participants, and to contextualize the findings within existing osteopathic research on ANS modulation. Methods: 51 osteopathic students were randomized into three groups: (1) an osteopathic test group (OTG) receiving listening tests; (2) a light pressure group (LPG) experiencing non-therapeutic light pressure; and (3) a control group (CG) receiving no intervention. Measurements of HR, rMSSD, and LF/HF ratio were collected during the first and last 30 s of the protocol utilizing validated software. Data from 48 participants were analyzed after excluding artifacts. Results: No significant changes in HR, rMSSD, or LF/HF ratio were observed in any group during the protocol. For OTG, the HR changed minimally (69.17 ± 9.58 beats per minute [bpm] to 69.10 ± 10.24 bpm; p=0.884), while the rMSSD and LF/HF ratio also showed no significant alterations (p=0.064 and p=0.106, respectively). Similar null findings were observed in the LPG and CG, suggesting that neither osteopathic tests nor light pressure induced measurable effects on the ANS markers chosen. Conclusions: This study found no evidence that osteopathic listening tests influence HR or HRV markers in healthy participants. Although listening tests serve as diagnostic tools for identifying somatic dysfunctions, they do not appear to exert therapeutic effects on ANS regulation. These findings contrast with previous studies on osteopathic manipulative treatment (OMT), which have demonstrated significant modulation of ANS activity. Future studies should investigate the differential effects of diagnostic tests and therapeutic techniques to better define the scope of the osteopathic interventions.

1 January 2025 in Case Reports in Oncology
Verified
Journal Article
Open access
WMWilliam Makis
William Makis
IBIlyes Baghli
Ilyes Baghli
PMPierrick Martinez
Pierrick Martinez
Background: Fenbendazole (FBZ), an inexpensive and widely accessible antiparasitic drug used in veterinary medicine, has garnered growing interest for its potential as an anticancer therapy. Preclinical studies suggest that FBZ exerts its anticancer effects through a wide variety of mechanisms. While FBZ has shown promise both in vitro and in vivo studies, clinical evidence supporting its use and efficacy in treating metastatic cancer is currently limited. Case Presentations: This report highlights 3 cases of patients with advanced cancer – including breast, prostate, and melanoma. Two patients achieved complete remission, and one achieved near-complete remission after incorporating FBZ into their treatment regimens alongside other therapies (excluding chemotherapy). All three patients tolerated FBZ without any reported adverse effects, and remission was sustained during follow-up periods ranging from 11 months to nearly 3 years. Conclusion: FBZ demonstrates potential as a novel promising therapeutic option for repurposing in oncology. Its ability to contribute to tumor regression and achieve disease remission warrants further clinical research to establish its efficacy and optimize its use.